Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:42 Suppl 4:S545-9.
doi: 10.3233/JAD-141482.

Preclinical Alzheimer's disease therapeutics

Affiliations
Review

Preclinical Alzheimer's disease therapeutics

Michael S Rafii. J Alzheimers Dis. 2014.

Abstract

In 2013, the Food and Drug Administration released draft guidance on drug development for early-stage Alzheimer's disease (AD). This guidance builds on the understanding that AD is a progressive disease with symptoms appearing long after neurodegeneration has begun. Preclinical AD relies on the conceptual distinction made between the presence of AD pathological processes and clinically observable symptoms. With the advent of new biomarkers that allow for presymptomatic detection of AD pathology, there now exists an opportunity to design and conduct clinical trials of putative disease-modifying drugs in the earliest stages of the disease when they are thought to have the greatest chance of success. As such, there are four clinical trials planned or underway for the secondary prevention of AD.

Keywords: Clinical trials; preclinical Alzheimer's disease.

PubMed Disclaimer

Substances

LinkOut - more resources